Cognex (NASDAQ:CGNX) Earns Neutral Rating from Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has initiated coverage on Cognex (NASDAQ:CGNX) with a neutral rating and a price target of $45.00, suggesting a potential upside of 1.37% from its current price.
• Other analysts have varying opinions, with Needham & Company rating it a "buy" at a higher price target of $45.00, while Goldman Sachs rated it a "sell" with a target of $32.00.
• Cognex reported earnings of $0.25 per share for the last quarter, exceeding estimates and marking a 4.2% year-over-year revenue increase.

Research analysts at JPMorgan Chase & Co. started coverage on shares of Cognex (NASDAQ:CGNX - Get Free Report) in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage set a "neutral" rating and a $45.00 price target on the scientific and technical instruments company's stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 1.37% from the company's current price.

Several other equities research analysts have also weighed in on CGNX. Needham & Company LLC boosted their target price on Cognex from $36.00 to $45.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. UBS Group upped their price target on Cognex from $53.00 to $58.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Melius upgraded Cognex from a "hold" rating to a "buy" rating and set a $60.00 price target for the company in a report on Thursday, July 10th. The Goldman Sachs Group upped their price target on Cognex from $29.00 to $32.00 and gave the stock a "sell" rating in a report on Thursday, June 12th. Finally, Citigroup reiterated a "neutral" rating and set a $37.00 price target (up from $30.00) on shares of Cognex in a report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $42.50.

Cognex Stock Performance

CGNX opened at $44.39 on Monday. The business has a 50 day moving average price of $39.81 and a 200 day moving average price of $33.04. Cognex has a twelve month low of $22.67 and a twelve month high of $45.23. The firm has a market cap of $7.45 billion, a P/E ratio of 62.52 and a beta of 1.50.

Cognex (NASDAQ:CGNX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The scientific and technical instruments company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. Cognex had a return on equity of 6.65% and a net margin of 13.13%.The firm had revenue of $249.09 million during the quarter, compared to analyst estimates of $246.70 million. During the same period in the previous year, the company earned $0.23 EPS. The company's revenue for the quarter was up 4.2% on a year-over-year basis. Cognex has set its Q3 2025 guidance at 0.240-0.290 EPS. As a group, analysts anticipate that Cognex will post 0.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Cognex news, EVP Sheila Marie Dipalma sold 2,000 shares of the company's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $45.03, for a total value of $90,060.00. Following the sale, the executive vice president directly owned 6,582 shares in the company, valued at $296,387.46. This represents a 23.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

Institutional Trading of Cognex

Large investors have recently made changes to their positions in the business. TD Waterhouse Canada Inc. bought a new stake in shares of Cognex during the second quarter worth $29,000. Penserra Capital Management LLC bought a new stake in shares of Cognex during the second quarter worth $29,000. Geneos Wealth Management Inc. grew its holdings in shares of Cognex by 402.2% during the first quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company's stock worth $27,000 after purchasing an additional 736 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Cognex by 439.4% during the first quarter. Farther Finance Advisors LLC now owns 971 shares of the scientific and technical instruments company's stock worth $29,000 after purchasing an additional 791 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Cognex by 155.3% during the first quarter. GAMMA Investing LLC now owns 1,062 shares of the scientific and technical instruments company's stock worth $32,000 after purchasing an additional 646 shares during the last quarter. Institutional investors own 88.12% of the company's stock.

Cognex Company Profile

Cognex Corporation provides machine vision products that capture and analyze visual information to automate manufacturing and distribution tasks worldwide. Its machine vision products are used to automate the manufacturing and tracking of discrete items, including mobile phones, electric vehicle batteries, and e-commerce packages by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.